Reviewed by Dr. Golsa Gholampour, MDMedically reviewed by Dr. Golsa Gholampour, MD. Last updated April 2026.
Why GLP-1 Medications Affect Birth Control
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) work partly by slowing gastric emptying. This is the process that moves food and medications from your stomach into your small intestine, where absorption occurs. When gastric emptying slows down, oral medications spend more time in the stomach and may be absorbed more slowly or less predictably.
- GLP-1 receptor agonists slow gastric emptying, which can reduce how well oral contraceptives are absorbed.
- The FDA label for semaglutide specifically warns about potential interactions with oral birth control pills.
- Non-oral contraception methods (IUDs, implants, patches, injections) are not affected by GLP-1 medications.
- Women starting GLP-1 therapy should use backup contraception for at least 4 weeks after starting or increasing their dose.
Oral birth control pills rely on consistent absorption to maintain the hormone levels needed to prevent pregnancy. If absorption is delayed or reduced, hormone levels may drop below the level needed for reliable pregnancy prevention. This is the same reason vomiting or severe diarrhea can compromise oral birth control effectiveness.
The FDA-approved prescribing information for Wegovy and Ozempic includes a specific note about this interaction. Novo Nordisk recommends that patients using oral contraceptives consider switching to a non-oral method or adding a backup method when initiating semaglutide therapy.
What the Clinical Evidence Shows
A pharmacokinetic study published in the journal Clinical Pharmacokinetics examined the interaction between semaglutide and a combined oral contraceptive containing ethinylestradiol and levonorgestrel. The study found that semaglutide reduced the peak concentration (Cmax) of ethinylestradiol by approximately 12% and delayed the time to peak concentration.
While a 12% reduction may sound modest, birth control pills are designed with a narrow margin for maintaining consistent hormone levels. Even small changes in absorption may affect effectiveness, especially during the first few weeks of GLP-1 therapy when gastric emptying effects are most pronounced.
Tirzepatide studies have shown similar patterns. The prescribing information for Mounjaro recommends that patients using oral hormonal contraceptives switch to a non-oral method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation.
The "Ozempic Baby" Phenomenon
There have been reports of unplanned pregnancies in women taking GLP-1 medications. While some of these cases involve reduced birth control effectiveness, there is another important factor at play.
Obesity is associated with reduced fertility. Excess body fat affects hormone regulation, ovulation, and reproductive function. When women lose significant weight on GLP-1 medications, their fertility can improve rapidly, sometimes before they realize it. Women who had been unable to conceive for years have reported unexpected pregnancies after starting semaglutide or tirzepatide.
This means women on GLP-1s face a two contributing factors: their oral birth control may be less effective, and their underlying fertility may be increasing at the same time. Both factors make reliable contraception especially important during GLP-1 therapy.
For more information about pregnancy considerations, see our guide on whether you can take Ozempic or Wegovy while pregnant.
Which Contraception Methods Are Affected
Not all birth control methods are equally vulnerable to GLP-1 interactions.
Methods that may be affected:
- Combined oral contraceptive pills (the most common type)
- Progestin-only pills (mini-pills)
- Any other oral hormonal medication
Methods that are not affected:
- Hormonal IUDs (Mirena, Kyleena, Liletta) deliver hormones directly to the uterus
- Copper IUDs (Paragard) contain no hormones at all
- Hormonal implants (Nexplanon) release hormones directly into the bloodstream
- Injectable contraceptives (Depo-Provera) bypass the digestive system entirely
- Contraceptive patches and vaginal rings absorb through the skin or vaginal mucosa
- Barrier methods (condoms, diaphragms) are mechanical and unaffected
If you are currently using oral birth control and starting a GLP-1 medication, a commonly recommended approach is to either switch to a non-oral method or add a barrier method like condoms as backup.
What the FDA Label Actually Says
The Wegovy prescribing information states: "Semaglutide delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications." It specifically calls out oral contraceptives as a medication class of concern.
The Mounjaro and Zepbound labels are even more direct, recommending that patients "switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation and for 4 weeks after each dose escalation step."
These warnings are based on pharmacokinetic data and clinical studies. They reflect data from clinical trials and pharmacokinetic studies that demonstrated measurable changes in oral medication absorption.
You can review the full list of GLP-1 medications and their safety profiles on our safety information page.
What to Discuss With Your Provider
Before starting any GLP-1 medication, women of reproductive age should have a discussion with their prescriber about contraception. Here are the key questions to ask:
Should I switch my birth control method? If you are on oral contraceptives, ask whether a non-oral method would be more appropriate during GLP-1 therapy.
How long should I use backup contraception? Most guidelines recommend backup protection for at least 4 weeks after starting the medication and 4 weeks after each dose increase.
What if I want to become pregnant? GLP-1 medications should be discontinued at least 2 months before a planned pregnancy (for semaglutide) due to the drug's long half-life.
Will my fertility change as I lose weight? Your provider should counsel you about the potential for improved fertility with weight loss, even if you were previously told conceiving would be difficult.
Are there any additional interactions? If you take other oral medications alongside birth control and a GLP-1, there may be additional effects on medication absorption.
How Timing and Dose Escalation Affect the Risk
The interaction between GLP-1 medications and oral birth control is not constant. It is most significant during two specific windows.
The first window is the initial weeks after starting GLP-1 therapy. Your body is adjusting to the medication, and the effects on gastric emptying are often most noticeable at this stage. Nausea, which is common during the first 2-4 weeks, further indicates that your digestive system is undergoing significant changes.
The second window occurs at each dose escalation. Every time your GLP-1 dose increases, gastric emptying slows further, and absorption patterns shift again. This is why the Mounjaro prescribing information recommends backup contraception for 4 weeks after each dose increase, not just at initiation.
Once you are on a stable maintenance dose and your body has fully adjusted, the impact may be less pronounced, but clinical data on long-term steady-state interaction is limited. Many providers recommend maintaining non-oral contraception throughout the duration of GLP-1 therapy to reduce uncertainty.
The Bottom Line
GLP-1 medications are effective tools for weight management and metabolic health, but they come with important considerations for women using oral contraception. The interaction is supported by prescribing information and pharmacokinetic studies in FDA labeling and clinical studies. The good news is that effective alternatives exist, and a simple conversation with your provider can ensure you stay protected.
If you are considering starting a GLP-1 medication, take the time to review your contraception plan first. It is one of the most important steps in your treatment preparation.
GLP-1 medications require a prescription and ongoing medical supervision. Always work with a licensed healthcare provider and verify that any telehealth platform or clinic uses board-certified clinicians and accredited pharmacies.
Sources
- Wegovy (semaglutide) Prescribing Information. Novo Nordisk. 2024.
- Mounjaro (tirzepatide) Prescribing Information. Eli Lilly. 2024.
- Kapitza C, et al. "Effect of semaglutide on the pharmacokinetics of oral contraceptives and metformin." Clinical Pharmacokinetics. 2023.
- FDA Drug Safety Communication: GLP-1 receptor agonist drug interactions. 2024.
- ACOG Practice Advisory: Contraception considerations with weight loss medications. 2025.